Hepatitis B Birth Dose Vaccination Activities in the ...
Transcript of Hepatitis B Birth Dose Vaccination Activities in the ...
Center for Global Health
Hepatitis B Birth Dose Vaccination Activities in the African Region
Community of Practice for HepB Birth Dose Introduction in the African Region Meeting 1: The Current State of HepB Birth Dose Introduction Efforts
March 17–18, 2021
Rania A. Tohme, M.D., MPHTeam Lead- Hepatitis B and Tetanus
Global Immunization Division (GID), US CDC
GID Activities Related to Hepatitis B Vaccination Globally
▪ Estimate Hepatitis B burden and track progress towards achievement of regional goals
▪ Improve coverage with Timely HepB-BD
▪ Support HepB-BD Introduction
▪ Innovation and research (Global)
▪ Support Global and Regional Verification of control/elimination targets (WPR, EUR, AMR, SEAR, EMR)—verification not established in AFRO
1. Compiling evidence on hepatitis B virus infection prevalence in children and assessing risk of MTCT of HBV
Rationale▪ True burden of HBV infection post- pentavalent vaccine introduction is largely
unknown in children in African Region ▪ Unsubstantiated hypothesis that mother to child transmission (MTCT) of HBV is
lower in Africa than other regions due to different genotypes▪ Need data from Africa to provide evidence for HepB-BD introduction and inform
NITAGs
Main methods▪ Use pre-collected specimens from population-based HIV serosurveys to test for
HBV infection in children and women of reproductive age▪ Conduct mother-child paired serosurveys to estimate the risk of MTCT of HBV▪ Advocate for integration of hepatitis B testing in children in HIV surveys, DHS,
MICS, and other nationally representative surveys
Assessing the Impact of hepatitis B vaccination and the need for Hepatitis B Vaccine Birth Dose in Sierra Leone, 2018
Objectives
▪ Determine HBsAg prevalence in mothers, their 4-24 months old infants and 5–9-year-old children
▪ Assess importance of maternal HBV biomarkers as risk factors for perinatal transmission of HBV
Methods
▪ Multi-stage cluster household survey in Bo, Bombali and Western area urban
▪ Random selection by PPS of ~ 2000 women, 2000 infants and 2000 children
Key results▪ HBsAg prevalence:
• Women: 9.8% • Infants: 1.3%• Children: 1.6%
▪ Prevalence of HBsAg was 8 times higher in children born to HBsAg positive mothers than those born to HBsAg negative mothers (5.9% vs 0.7%)
▪ Maternal HBsAg, HBeAg and HBV DNA associated with infants’ HBV infection• >90% had detectable HBV DNA
Breakwell L, et al. Assessing the Impact of the Routine Childhood Hepatitis B Immunization and the Need for Hepatitis B Vaccine Birth Dose in Sierra Leone, 2018. ID week 2020, Abstract 1055. OFID 2020:7 (Suppl 1) • S557https://academic.oup.com/ofid/article/7/Supplement_1/S557/6057448
Assessing the Prevalence of HBV infection among children in Nigeria
Objectives▪ Estimate chronic HBV infection among children
<10 years old to assess vaccine impact and progress towards regional and global HepBtargets
▪ Validate use of dried blood spots (DBS) for testing hepatitis B surface antigen (HBsAg) and HBV DNA in serosurveys- ― implications for use and potential for better integration in future serosurveys
Methods▪ Testing specimens from Nigeria AIDS indicator
and impact survey• 7600 children aged <10 years stratified by
North/South and age group (<5 and 5-9 y.o)
Preliminary results/Not finalized ▪ HBsAg prevalence in children: 4.4%
Next steps▪ Finalize lab testing and analyze data▪ Test serum specimens from women
and validate with DBS
Local Partners▪ Nigeria Center for Disease Control▪ Nigeria Federal Ministry of Health▪ National Primary Healthcare
Development Agency (NPHCDA)
Determining the Risk of Hepatitis B Virus Mother-to-Child Transmission in Ghana
Objectives▪ Estimate the seroprevalence of HBsAg among pregnant
women presenting to antenatal care and their Infants aged 6-9 months
▪ Evaluate association between risk of HBV MTCT and maternal markers of infection (HBsAg, HBeAg, HBV DNA, and HBV genotype)
▪ Estimate the seroprevalence of chronic HBV infection among children aged 2-9 years old
Methods▪ Prospective cohort study▪ Screening 16,700 women attending ANC clinics and then
follow-up infants born to HBsAg positive women and equal number of HBsAg negative women for HBsAg testing
▪ Test another sibling aged 2 -9 years for HBsAg
Next steps▪ Obtain ethical approval
and Implement the project
Local Partners▪ Ghana Health Service
– Expanded program on Immunization
– National viral hepatitis control program
– National Public Health and Reference Laboratory
▪ Noguchi Memorial Institute for Medical Research
▪ African Field Epidemiology Network (AFENET)
2. Improve coverage with Timely HepB-BD
▪ Completed activities
– Supported WHO AFRO with development of HepB-BD post-introduction assessment Tools
– Participated in HepB-BD post-introduction assessments
• Botswana, Namibia, Nigeria, Mauritania, São Tomé and Príncipe(STP), Senegal
– Assessment of the cost-effectiveness of universal vs. selective HepB-BD for preventing chronic infections or HBV-related deaths in STP
• Provided key evidence that selective vaccination was not cost-effective and informed the need for universal HepB-BD
– Hagan JE, Carvalho E, Souza V, et al. Selective hepatitis B birth-dose vaccination in São Tomé and Príncipe: A program Assessment and cost-effectiveness study. Am J. Trop Med. Hyg. 2019; 10: 891-898
Improving Timely HepB-BD Coverage in Nigeria
Objectives▪ Assess whether implementation of a package of HepB-BD interventions
will lead to improved total and timely HepB-BD in Enugu and Kaduna States
▪ Package components– Training MCH and EPI staff about the importance of and methods for
delivering timely HepB-BD and implement regular supervisory visits– Educating pregnant women during ANC visits about importance of health
facility (HF) delivery, and HepB-BD administration – Training community health workers (CHW) to link pregnant women in the
community to HF for delivery and HepB-BD administration– Engage with community leaders and civil society to encourage HepB-BD
vaccination
Methods▪ Control LGAs and intervention LGAs (urban and rural)-14 HFs in each arm▪ Pre- and post-intervention assessment
– Pre- and post- intervention assessment of total and timely HepB-BD coverage in intervention and control LGAs
– Identify barriers and perspectives of healthcare providers related to the administration of timely hepatitis B birth
– Assess the impact of HepB-BD focused education on increasing HepB-BD knowledge, attitudes, and practices (KAP) among HCWs and pregnant women
– Assess the impact of CHW training on the importance of and methods for line listing and linkage of pregnant women and newborns to health facilities
Local Partners▪ National Emergency Routine Immunization Coordination Centre (NERICC)▪ Nigeria Stop Transmission of Polio (NSTOP) program ▪ African Field Epidemiology Network (AFENET)
Improving Timely HepB-BD Coverage in Nigeria
3. Support HepB-BD Introduction
▪ Completed Activities– Provide evidence for HepB-BD introduction
• Review paper on the Status of HepB control in African Region: Breakwell L, Tevi-Benissan C, Childs L, Mihigo R, Tohme RA. The Status of Hepatitis B Control in the African Region. The Pan African Medical Journal 2017; 27 (Supp3):17. doi:10.11604/pamj.supp.2017.27.3.11981
– Support countries in generating evidence needed by NITAGs for HepB-BD introduction (Uganda, Tanzania)
▪ Advocacy and support to build the platform for HepB-BD introduction in DRC in collaboration with WHO/AFRO
Ethiopia HepB-BD Pilot Introduction
▪ Support pilot HepB-BD introduction in selected woredas in Ethiopia to inform national scale up
▪ Ethiopia Federal Ministry of Health/MCH and EPI leading the implementation with support from US CDC and WHO
▪ Objectives– Identify challenges & barriers to HepB-BD vaccination
• Document lessons learned & best practices• Assess acceptance and feasibility of HepB-BD vaccination among
HCWs and mothers– Calculate timely HepB-BD coverage for HF and home births– Determine cost of introducing and maintaining HepB-BD– Assess impact of HepB-BD - HBsAg prevalence in children
What is Next?
▪ Continue to support countries with HepB-BD introduction, generation of evidence and implement key interventions to improve coverage
▪ Support WHO/AFRO in establishing a regional verification mechanism for hepatitis B control/elimination
▪ Evaluate use of HepB-BD outside the cold chain in the African context– Very successful strategy documented to improve timely HepB-BD coverage
among home births in Asia▪ Assess impact of HepB-BD in countries with good coverage (e.g. Namibia,
Senegal)▪ Advocate for more countries to introduce the Hepatitis B birth dose in Africa
– No child deserves to be born with HBV infection and later suffer as an adult from liver cancer—Hepatitis B is a vaccine preventable disease and hepatitis B vaccine is the first anti-cancer vaccine
Impact of Hepatitis B Vaccination on Disease Burden
Child L, Roesel S, Tohme RA. Vaccine 2018; 36: 6-14.
South East Asia Region
0
500,000
1,000,000
1,500,000
2,000,000
2,500,000
3,000,000
3,500,000
4,000,000
4,500,000
5,000,000
0
10
20
30
40
50
60
70
80
90
100
199
0
199
2
199
4
199
6
199
8
200
0
200
2
200
4
200
6
200
8
201
0
201
2
201
4
Ch
ron
ic i
nfe
cti
on
s
Va
cc
ina
tio
n c
ove
rag
e
Year of birth
Hepatitis B vaccine 3rd dose
Hepatitis B vaccine birth dose
Wiesen E, Diortista S, Li X. Vaccine 2016; 34:2855-2862
0
500,000
1,000,000
1,500,000
2,000,000
2,500,000
0
10
20
30
40
50
60
70
80
90
100
Nu
mb
er
of
chro
nic
HB
V i
nfe
ctio
ns
He
pB
vac
cin
atio
n c
ov
ve
rag
e %
Year
HepB3 vaccination coverage
HepB-BD vaccination coverage
Number of chronic HBV infections
Western Pacific Region
For more information, contact CDC1-800-CDC-INFO (232-4636)TTY: 1-888-232-6348 www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.